Grifols, S.A.
GRFS Healthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue grew 5.76%, EPS grew 466.9%, free cash flow grew 300.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow GRFS
Grifols, S.A. (GRFS) P/E ratio
As of 16 October 2026, Grifols, S.A. (GRFS) trades at a P/E ratio of 8.5×. Over the past ten years it has ranged from 7.8× (July 2026) to 57.8× (December 2023); the current reading is higher than 2% of that period. That is below the Drug Manufacturers General industry median of 24.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 10.4× | (50.41%) |
| FY2024 | 20.9× | (62.22%) |
| FY2023 | 55.3× | 121.25% |
| FY2022 | 25.0× | 21.90% |
| FY2022 | 20.5× | 3.65% |
| FY2021 | 19.8× | 9.03% |
| FY2021 | 18.1× | 2.77% |
| FY2020 | 17.6× | (14.36%) |
| FY2020 | 20.6× | 1.33% |
| FY2019 | 20.3× | 10.42% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 8.9× | (14.23%) |
| Dec 2025 | 10.4× | (57.76%) |
| Sep 2025 | 24.5× | 10.18% |
| Jun 2025 | 22.2× | 11.50% |
| 28 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AMRN Amarin Corporation PLC compare | n/m |
| GRFS Grifols, S.A. | 8.5× |
| NVO Novo Nordisk A/S compare | 9.5× |
| BMY Bristol Myers Squibb Company compare | 13.2× |
| GSK GSK PLC Sponsored ADR compare | 15.4× |
| OGN Organon & Co. compare | 17.4× |
| SNY Sanofi compare | 21.3× |
| BIIB Biogen Inc. compare | 41.0× |
| NSRX Nasus Pharma Ltd. compare | — |
| Drug Manufacturers General industry median | 24.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)